• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Uveitis  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Eric B. Suhler, MD, MPH; Justine R. Smith, MBBS, PhD; Tracy R. Giles, BS; Andreas K. Lauer, MD; Michael S. Wertheim, MBChB, MRCOphth; Daryl E. Kurz, MD; Paul A. Kurz, MD; Lyndell Lim, MBBS; Friederike Mackensen, MD; Terri D. Pickard, COT; James T. Rosenbaum, MD

Arch Ophthalmol. 2009;127(6):819-822.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

During the last decade, tumor necrosis factor blockers have become well accepted as useful agents in the armamentarium of treatments for refractory uveitis.^1-2 Of the 3 commercially available tumor necrosis factor blockers, published reports suggest that infliximab (Remicade) is more effective for the treatment of uveitis than etanercept (Enbrel),³ although to our knowledge head-to-head randomized studies have not been performed. There is a relative paucity of published experience on the use of the third drug, adalimumab (Humira). Several retrospective studies have reported benefits using infliximab for uveitis.^1-3 In 2005, we published preliminary results from the first 23 patients enrolled in our prospective trial of infliximab . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Uncovering the Risks of Immunosuppressive Therapy in Patients With Uveitis
Debra A. Goldstein
Arch Ophthalmol. 2009;127(6):799-800.
EXTRACT | FULL TEXT  

A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes
Eric B. Suhler, Justine R. Smith, Michael S. Wertheim, Andreas K. Lauer, Daryl E. Kurz, Terri D. Pickard, and James T. Rosenbaum
Arch Ophthalmol. 2005;123(7):903-912.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Why HLA-B27? My Thirty-Year Quest: The Friedenwald Lecture
Rosenbaum
IOVS 2011;52:7712-7715.
FULL TEXT  

Successful Treatment of Refractory Sympathetic Ophthalmia in a Child With Infliximab
Gupta et al.
Arch Ophthalmol 2011;129:250-252.
FULL TEXT  

Investigation and management of uveitis
Guly and Forrester
BMJ 2010;341:c4976-c4976.
FULL TEXT  

The Dream of Biologics in Uveitis
Okada
Arch Ophthalmol 2010;128:632-635.
FULL TEXT  

Anti-Tumor Necrosis Factor Therapies in Immune-Mediated Rheumatic Diseases. Other Observations from the Clinic
RUSSELL and ROSENBAUM
The Journal of Rheumatology Supplement 2010;85:53-62.
ABSTRACT | FULL TEXT  

Uncovering the Risks of Immunosuppressive Therapy in Patients With Uveitis
Goldstein
Arch Ophthalmol 2009;127:799-800.
FULL TEXT